Furthermore, DDR mutations, such as ATM, PTEN, MRE11, and FANCA mutations, have been found in a large proportion of lung cancer patients, as well as BRCA1/2 mutations in 5% of patients, justifying the administration of PARP inhibitors to lung cancer patients [13, 14]. Here, MRE11 is linked to lung carcinoma.